4-Chlorbenzoyl Berbamine, a Novel Derivative of the Natural Product Berbamine, Potently Inhibits the Growth of Human Myeloma Cells by Modulating the NF-κB and JNK Signalling Pathways. (25th November 2016)

• Record Type: Journal Article
• Authors: Liang, Yun; He, Xin; Li, Xian; Zhang, Xuzhao; Zhang, Xiaohong; Zhang, Lei; Qiu, Xi; Zhao, Xiaoying; Xu, Rongzhen
• Is Part Of: Cancer investigation. Volume 34:Number 10(2016)
• Page Start: 496
• Page End: 505
• Publication Date: 2016-11-25
• Subjects: Multiple myeloma -- berbamine derivatives -- nuclear factor-kappaB -- JNK -- apoptosis; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2016.1235709
• Languages: English
• ISSNs: 0735-7907

Abstract

ABSTRACT: Multiple myeloma (MM) remains incurable despite the development and the use of new agents. In our studies, we found that 4-chlorbenzoyl berbamine (BBMD9), a novel synthetic derivative of berbamine, inhibited the proliferation of MM cells in dose- and time-dependent manners. Flow cytometric (FCM) analysis revealed that MM cells were arrested in the G1 phase and that apoptotic cells increased in a time-dependent manner. Moreover, the BBMD9 treatment downregulated IKKα and IKKβ, inhibited p-IκBα, and blocked p65 nuclear localization. Consistently, NF-κB downstream targets, such as cyclinD1 and survivin, were also reduced. In addition, BBMD9 phosphorylated the activity of JNK and c-Jun.